UK & Europe AA Gill takes swipe at NICE in final column NHS initially denied late writer immunotherapy.
News Opdivo gains European approval for Hodgkin lymphoma Latest approval for Opdivo good news, but won't make up for lung cancer setback
Views & Analysis NICE and NHS England unveil ‘fast-track’ and affordability s... NHS England will be able to control cost impact of NICE decisions more directly.
ESMO2016 Cancer Market Commentary: Keytruda’s triumph not the last wo... Despite Keytruda's overwhelming victory, it's not over yet in NSCLC
ESMO2016 Cancer market commentary: Roche’s Tecentriq muscles into NSC... Roche's PD-L1 drug has generated impressive data in second line lung cancer
News BMS and Nektar to pair Opdivo with natural killer cell drug BMS and Nektar's combination latest in frenzied immunotherapy field
Market Access Consolidating data strategy for global success: Insights fro... At Frontiers Health 2025, Drew McCormick, Head of Data and Analytics at EVERSANA, emphasised a critical truth: data strategy is launch strategy.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
